GSK drug Jemperli met the main goal of a pivotal Phase 2 test in patients with a rare type of rectal cancer, paving the way for regulatory submissions. This antibody drug has already received a voucher to speed up its review under a new FDA pilot program.
The post GSK Eyes FDA Filing After Immunotherapy Succeeds in Key Rectal Cancer Study appeared first on MedCity News.
Tick-Borne Nairoviruses Use OTU Proteases to Evade Human Antiviral Signals
Summer is peak tick season, and with it comes familiar threats like Lyme disease and Rocky Mountain spotted fever. But scientists say another group of
